Navigation Links
MedImmune's Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
Date:8/23/2007

Native American infants, with an overall incidence and severity of adverse events (AEs) that were similar between the motavizumab and the placebo groups. The mortality rates were not statistically different between groups (0.4 percent in the placebo arm, n=2 and 0.3 percent in the motavizumab arm, n=3) and were not considered to be related to the study drug. As was suggested in the pivotal Phase 3 trial conducted in high-risk, preterm infants, rates of hypersensitivity related skin rashes within two days of dosing were seen in about one percent of treated children in the motavizumab group.

MedImmune's Commitment to RSV Prevention

MedImmune is a world leader in the development of innovative therapeutic biologic products to prevent RSV disease. In 1996, MedImmune launched the first anti-RSV drug, RespiGam(R) (respiratory syncytial virus immune globulin intravenous (human) (RSV-IGIV)), which was a polyclonal antibody administered via four-hour intravenous infusion. In 1998, MedImmune introduced Synagis, which was a significant product improvement as a monthly intramuscular injection for the prevention of severe RSV, as well as being the first MAb to receive U.S. Food and Drug Administration (FDA) approval for an infectious disease. With the development of motavizumab, MedImmune continues to reinforce its commitment to developing anti-RSV products. In a head-to-head comparative Phase 3 trial with Synagis, motavizumab met its primary endpoint of reducing RSV-related hospitalizations in high-risk pediatric patients and met its secondary endpoint of reducing medically attended, outpatient respiratory tract infections in that patient group. MedImmune is also developing a small-molecule product candidate to prevent RSV as well as a vaccine against RSV, both of which are in Phase 1 clinical trials.

About RSV

Each year, up to 125,000 infants in the U.S. are hospitalized with severe RSV infections, the leading cause of lower respiratory tract infections
'/>"/>

SOURCE MedImmune, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
7. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery Calcification, a Predictor of Cardiovascular Events, in Women aged 50-59 taking Estrogen Therapy
8. Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
11. Data Suggest Cymbalta Reduced Severity of Night Pain in Patients with Diabetic Nerve Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" ... three-month period ended March 31, 2015. First quarter financial highlights ... increase of 19% as compared to $7.0 million in ... increased 41% year-over-year, enabled by the return of normalized ... in the fourth quarter of 2014; , Service ...
(Date:5/6/2015)... , May 6, 2015 ... therapy with dolutegravir and rilpivirine   ... a Phase III clinical trial programme to evaluate ... rilpivirine (Edurant® [1] ) as maintenance therapy for ... comprises two replicate studies evaluating 48 week viral ...
(Date:5/6/2015)... Woodford Patient Capital Trust ... and the Bill & Melinda Gates Foundation to ... leading monoclonal antibody biopharmaceutical company, announced today that ... to complete a US$90 million Series B financing. ... Patient Capital Trust plc (LSE:WPCT,"Woodford") and Malin Corporation ...
Breaking Medicine Technology:Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10Kymab Secures US$90 Million Funding 2Kymab Secures US$90 Million Funding 3Kymab Secures US$90 Million Funding 4
(Date:5/6/2015)... Norcross, GA (PRWEB) May 06, 2015 ... has chosen Hexagon Geospatial technology to manage and distribute ... , Australia is one of the driest continents on ... supply through times of drought and erratic seasonal rainfalls ... water supply solutions. , Water NSW manages raw water ...
(Date:5/6/2015)... Mateo, Calif. (PRWEB) May 06, 2015 ... SafeMonk today announced a strategic partnership to help ... the cloud. The two industry-leading companies are teaming up ... platform. , “We’re thrilled to welcome SafeMonk ... to us that the people behind SafeMonk, the global ...
(Date:5/6/2015)... 2015 National Physical Fitness and Sports ... within the U.S. Department of Health and Human Services ... Fitness and Sports Month. It is dedicated to ... to health. Throughout the month of May, Americans ... fit. , The HHS details the benefits of regular ...
(Date:5/6/2015)... May 06, 2015 Most people in the ... nursing or other care after age 65. But less than ... for it or even talking about it, reports the May ... people risk two problems. One is losing control over the ... families," says Dr. David Grabowski, a professor of health care ...
(Date:5/6/2015)... Herndon, VA (PRWEB) May 06, 2015 ... its CIT GAP Funds has invested in e-Kare, Inc. ... speeds the assessment and monitoring of chronic wounds. , ... burn, and complex surgical wounds that affect over 6.5 ... in 2013 as a spin-off enterprise from the Children’s ...
Breaking Medicine News(10 mins):Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:Sookasa Grows Globally With SafeMonk Partnership 2Health News:Sookasa Grows Globally With SafeMonk Partnership 3Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 2Health News:Narconon Arrowhead Issues Guide for Physical Fitness and Sports Month 3Health News:Start Planning Now for Long-Term Care, from the May 2015 Harvard Health Letter 2Health News:CIT GAP Funds Invests in e-Kare 2Health News:CIT GAP Funds Invests in e-Kare 3
... 20 MCG Capital,Corporation (Nasdaq: MCGC ) today ... support the acquisition of Gould & Lamb, LLC by ... services company that is unique to,the workers, compensation industry. ... the workers, compensation industry,since 2001. Having completed in excess ...
... Hospitals are dangerous,places and the danger is even greater ... temps are relied on more than usual, and the ... McCaughey, Ph.D., Chairman of the Committee to Reduce Infection,Deaths, ... that hospital staff are eager to improve your safety ...
... DRAXIMAGE strong competitive position in ... Dec. 20 /PRNewswire-FirstCall/ - DRAXIMAGE, the,radiopharmaceutical division ... has appointed GE Healthcare, an industry leader ... DRAXIMAGE(R) Sestamibi in the United,States. DRAXIMAGE(R) Sestamibi ...
... 10 Law Offices of Howard G. Smith,announces ... be a lead plaintiff in,the securities class action ... common stock of Threshold Pharmaceuticals, Inc. ("Threshold,Pharmaceuticals" or ... 2005,and July 14, 2006 (the "Class Period"), including ...
... XCPT, LLC has entered into a,representation agreement ... dentists throughout the world. XCPT,s software is ... recognizing the importance of visual learning during,treatment planning. ... step of the,dental treatment process as the clinician ...
... Calif., Aug. 10 Mike Huckabee,will be the keynote ... at the Disneyland(R) Hotel in Anaheim, CA. The,event will ... "We are very honored to have a national ... who understands the importance of,Christian higher education as our ...
Cached Medicine News:Health News:MCG Capital Invests in Gould & Lamb 2Health News:How to Survive an Unexpected Trip to the Hospital During Christmas and New Years 2Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 2Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 3Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 4Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 5Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 6Health News:DRAXIS Names GE Healthcare as Exclusive Distributor of DRAXIMAGE(R) Sestamibi in USA 7Health News:Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc. 2Health News:XCPT(TM) Patient Engagement and Communication Software Signs Representation Agreement with Lifecore Biomedical, Inc. (Nasdaq: LCBM) 2Health News:Presidential Candidate and Former Arkansas Governor Mike Huckabee to Be Keynote Speaker for Hope International University's 'Celebrate Hope' Dinner at Disneyland(R) Hotel 2
The new TOPCON 8800 Series of auto refractors and auto kerato-refractors satisfies the needs of today's demanding eyecare practice !...
The perfect tool to prepare for in-service or licensing exams, for recertification, or for use as a clinical refresher....
... Med TruFlow™ Oxygen flowmeter with a Lexan®inner ... covering calibration and manufacturing defects. A wide ... most needs. Also available with all popular ... take-off and double unit configurations. Our extra ...
... TruFlow™ Oxygen flowmeter with a Lexan®inner calibrated ... calibration and manufacturing defects. A wide range ... needs. Also available with all popular inlet ... and double unit configurations. Our extra large ...
Medicine Products: